A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-allylamino-17-demethoxygeldanamycin (17AAG) in Patients with Solid Tumors

PURPOSE: Both Hsp90 and checkpoint kinase 1 (Chk1) have emerged as novel therapeutic targets. We conducted a phase I study of irinotecan and the Hsp90 inhibitor 17AAG, which can also down-regulate Chk1, in patients with solid tumors. EXPERIMENTAL DESIGN: During the dose-escalation phase, patients re...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tse, Archie. N., Klimstra, David S., Gonen, Mithat, Shah, Manish, Sheikh, Tahir, Sikorski, Rachel, Carvajal, Richard, Mui, Janet, Tipian, Caroll, O’Reilly, Eileen., Chung, Ki, Maki, Robert, Lefkowitz, Robert, Brown, Karen, Manova-Todorova, Katia, Wu, Nian, Egorin, Merrill J., Kelsen, David, Schwartz, Gary. K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3996559/
https://ncbi.nlm.nih.gov/pubmed/18927314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky